Fourth quarter (2023-04-01 - 2023-06-30)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
Fiscal year (2022-07-01 - 2023-06-30)
The Group's net sales amounted to
The Group's loss after financial items amounted to
Result per share amounted to
The solidity as of 2023-06-30 was 37% (88%)**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 30th of
** Solidity: Equity divided by total capital.
Highlights during the fiscal year
Fourth quarter (2023-04-01 - 2023-06-30)
- June -
ODI Pharma secured loan financing ofEUR 350,000 from an external international party in order to create flexibility in the operations.
Third quarter (2023-01-01 - 2023-03-31)
- January -
ODI Pharma received approval from theOffice for Registration of Medicinal Products , Medical Devices and Biocidal Products (URPL) inPoland for its Marketing Authorization Holder (MAH) application. The approval means thatODI Pharma has the right to distribute and sell its medical cannabis products on the Polish market.
Second quarter (2022-10-01 - 2022-12-31)
- December -
ODI Pharma held its Annual General Meeting. A summary of the resolutions is available onODI Pharma's website (https://www.odipharma.com/).
First quarter (2022-07-01 - 2022-09-30)
- No significant highlights during the period.
Highlights after the end of the fiscal year
- Augusti -
ODI Pharma entered through its Polish subsidiary into a collaboration agreement ("Agreement") with Synoptis Pharma Sp. Z o.o. ("Synoptis") under which ODI becomes the exclusive supply partner for medicinal cannabis flos products to Synoptis for a period of 5 plus additional optional 3.5 years covering all Eastern and Southeastern European markets, includingPoland ,Czech Republic ,Ukraine ,Croatia etc.
Comments by CEO
As we reflect on the conclusion of another fiscal year, I feel a sense of accomplishment and enthusiasm to share the progress made by
In
To strengthen our financial flexibility and support our operations, we are pleased to announce that we have secured a loan financing of
In August we were pleased to announce that a new collaboration agreement with Synoptis Pharma Sp. Z o.o. through our Polish subsidiary. This agreement designates ODI as the exclusive supplier of medicinal cannabis flos products to Synoptis across Eastern and Southeastern European markets, reinforcing our role as a key player in the region. With coverage in 23 countries and a range of products, this partnership solidifies ODI's position as a primary medicinal cannabis supplier, reflecting our commitment to innovation and strategic growth.
As we express our gratitude to our dedicated shareholders for their unwavering support and belief in our vision, we remain committed to our core mission of making a positive impact on the lives of patients. The approval of our MAH application in
As we embark on a new fiscal year, we do so with a sense of optimism. We will continue to strengthen our market presence, explore new opportunities, and drive innovation in the realm of medicinal cannabis and CBD-infused skincare products. Our commitment to excellence and dedication to improving lives remain at the forefront of all that we do.
Derek Simmross
CEO,
For more information on
Derek Simmross, CEO,
E-mail: info@odipharma.com
https://news.cision.com/odi-pharma/r/odi-pharma-ab--publication-of-year-end-report-for-the-fiscal-year-2022-2023,c3823549
https://mb.cision.com/Main/19043/3823549/2251298.pdf
(c) 2023 Cision. All rights reserved., source